Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that stroma-targeting by tocilizumab in
patients with adenocarcinoma of the esophagus or gastroesophageal junction with highly
activated stroma increases efficacy of chemoradiotherapy measured by pathological response
according to the Mandard criteria. Patients will be grouped for ADAM12, a non-invasive
blood-borne marker of stromal activation.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)